267 results on '"Agerberth B"'
Search Results
2. L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
3. Differential expression of enteric neuroimmune-network in invasive and acute watery diarrhoea
4. Analysis of sera from narcoleptic patients: autoantibodies stain distinct cell populations in rat brain and influence sleep patterns: 15:5
5. Vernix caseosa as a multi-component defence system based on polypeptides, lipids and their interactions
6. Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood
7. Phylogeny, processing and expression of the rat Cathelicidin rCRAMP: a model for innate antimicrobial peptides
8. Hsp90 binds CpG oligonucleotides directly: implications for Hsp90 as a missing link in CpG signaling and recognition
9. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. (Colon)
10. The antimicrobial peptide LL-37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils – implications for asthma
11. Decreased pulmonary levels of the anti-inflammatory Clara cell 16 kDa protein after induction of airway inflammation in asthmatics
12. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema
13. Endogenous antimicrobial peptides in fighting infections: 64
14. Antimicrobial Peptide LL-37 Internalized by Immature Human Dendritic Cells Alters their Phenotype
15. Malassezia sympodialis differently affects the expression of LL-37 in dendritic cells from atopic eczema patients and healthy individuals
16. Processing and activity of the mature rat cathelicidin rCRAMP
17. The rat cathelicidin rCRAMP is present in the brain
18. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa
19. Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia
20. Potent Inducers of Endogenous Antimicrobial Peptides for Host Directed Therapy of Infections
21. SAT0187 The Antimicrobial Peptide LL-37 and Type I Interferon in Idiopathic Inflammatory Myopathies
22. Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.
23. [Natural immunity--first line defense. New treatment against infections and autoimmune diseases in sight]
24. No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis
25. Host Antimicrobial Defence Peptides in Human Disease
26. No Evidence of Pathogenic Involvement of Cathelicidins in Patient Cohorts and Mouse Models of Lupus and Arthritis
27. A3.7 No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis
28. Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood
29. AB0100 Identification of the antimicrobial peptide LL-37 as a potential mediator of synovial inflammation in RA
30. Differential expression of enteric neuroimmune‐network in invasive and acute watery diarrhoea
31. We-P11:277 antimicrobial peptide LL-37 in human atherosclerosis
32. 188 Human Meconium Contains Antimicrobial Peptides/Proteins
33. 426 Expression of a Human Cathelicidin Antimicrobial Peptide, LL-37, in Amniotic Fluid with Neonatal or Maternal Infection
34. 30 Antimicrobial Components of Vernix Caseosa
35. 51 The Human Cathelicidin: Another Antimicrobial Peptide of Urinary Tract
36. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37
37. Phylogeny, processing and expression of the rat Cathelicidin rCRAMP: a model for innate antimicrobial peptides
38. Host Antimicrobial Defence Peptides in Human Disease.
39. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.
40. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.
41. NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells
42. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity.
43. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.
44. PEC-60 increases dopamine but not GABA release in the dorsolateral neostriatum of the halothane anaesthetized rat. An in vivo microdialysis study
45. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine
46. Molecular cloning of PEC-60 and expression of its mRNA and peptide in the gastrointestinal tract and immune system.
47. Protecting Effects of Vasoactive Intestinal Polypeptide on Lymphocytes Against Metal Toxicity
48. Reserpine treatment increases PEC-60-like immunoreactivity in the substantia nigra of the male rat as determined by radioimmunoassay
49. PEC-60, a novel porcine 60-residue intestinal peptide, reduces dopamine utilization in discrete parts of the neostriatum of the male rat following an intracerebroventricular injection
50. Vasopressor effects of intracerebroventricular injections of PEC-60, a novel porcine 60-residue intestinal peptide, in the awake unrestrained male rat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.